Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03599518
- Locations
- 🇯🇵
Aichi Cancer Center, Chikusa, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Kindai University Hospital, Sayama, Osaka, Japan
Phase I Study of the Combination of Anlotinib With Gefitinib
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 9
- Registration Number
- NCT03602027
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03486496
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
- Conditions
- Advanced NSCLC With EGFR Mutation
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03457337
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03399669
- Locations
- 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03381430
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: pemetrexed/cisplatin
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Guangzhou Medical University
- Target Recruit Count
- 178
- Registration Number
- NCT03374280
- Locations
- 🇨🇳
The first affiliated hospital of Guangzhou MC, Guangzhou, Guangdong, China
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
- Conditions
- EGFR-mutant Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT03333343
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT03292133
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03267654
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital;, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.